![]() |
市場調查報告書
商品編碼
1517637
螢光導引手術系統市場 - 類型(SPY 系統、PDE 系統、VS3 銥系統)、手術(開放式、腹腔鏡/內視鏡)、應用(癌症、心血管)- 全球預測(2024 年 - 2032 年)Fluorescence Guided Surgery Systems Market - Type (SPY System, PDE System, VS3 Iridium System), Surgery (Open, Laparoscopic/Endoscopic), Application (Cancer, Cardiovascular) - Global Forecast (2024 - 2032) |
由於癌症盛行率不斷上升以及對更精確手術干預的強烈需求,螢光引導手術系統市場規模預計從 2024 年到 2032 年將以 16.3% 的複合年成長率擴大。根據世界衛生組織的數據,2022 年將通報約 2,000 萬新癌症病例,導致約 970 萬人死亡。這些系統使外科醫生能夠即時可視化腫瘤和其他關鍵結構,以提高腫瘤切除的準確性並最大限度地減少對周圍健康組織的損害。這項技術在腫瘤學中特別有益,其中惡性組織的精確切除對於患者的治療效果至關重要。
對醫療基礎設施的投資不斷增加,以及醫療保健提供者對先進手術技術優勢的認知不斷提高,將影響市場的成長。政府和私營部門實體正在大力投資升級醫療設施,並為其配備最先進的手術工具,以改善病患照護。螢光成像技術的不斷進步,例如新型螢光染料和顯影劑的開發,進一步將螢光引導手術的應用範圍從腫瘤學擴展到神經外科、心血管外科和骨科等領域。
該行業分為類型、手術、應用和區域。
根據類型,PDE 系統領域的螢光導引手術系統市場價值預計在 2024 年至 2032 年期間將出現強勁成長,因為它能夠增強各種疾病的檢測和治療。 PDE 系統利用螢光染料選擇性地積聚在病變組織中,使它們在手術過程中在專門的成像設備下高度可見。這項技術還允許外科醫生精確識別肉眼或傳統影像方法可能看不到的腫瘤邊緣和殘留癌細胞。
在手術方面,腹腔鏡/內視鏡手術領域的螢光導引手術系統產業預計將在2024 年至2032 年實現顯著的複合年成長率。縮短恢復時間並減少併發症,從而有利於這種成長。螢光導引系統還透過提供血管、淋巴結和腫瘤等關鍵結構的即時可視化來提高腹腔鏡和內視鏡手術的精確度和安全性。
亞太地區螢光導引手術系統產業預計將在 2024 年至 2032 年持續成長。中國、印度和日本不斷增加的醫療保健支出和基礎設施發展導致大量投資用於升級醫療設施和採用先進的外科技術。癌症和其他慢性疾病發生率的上升也推動了對創新診斷和治療解決方案的需求,以實現更有效的腫瘤檢測。醫療保健技術的不斷進步以及醫療保健提供者對螢光引導手術益處的認知不斷增強也推動了該區域市場的成長。
Fluorescence Guided Surgery Systems Market size is expected to expand at 16.3% CAGR from 2024 to 2032 driven by the increasing prevalence of cancer and the strong need for more precise surgical interventions. As per WHO, in 2022, approximately 20 million new cancer cases were reported, resulting in around 9.7 million fatalities. These systems enable surgeons to visualize tumors and other critical structures in real-time for enhancing the accuracy of tumor removal and minimizing damages to surrounding healthy tissues. This technology is particularly beneficial in oncology, where precise excision of malignant tissues is crucial for patient outcomes.
The increasing investments in healthcare infrastructure and the rising awareness among healthcare providers about the benefits of advanced surgical technologies will influence the market growth. Governments and private sector entities are investing heavily in upgrading healthcare facilities and equipping them with state-of-the-art surgical tools to improve patient care. The continuous advancements in fluorescence imaging technology, such as the development of new fluorescent dyes and imaging agents, are further expanding the applications of fluorescence-guided surgery beyond oncology to fields like neurosurgery, cardiovascular surgery, and orthopedics.
The industry is segmented into type, surgery, application and region.
Based on type, the fluorescence guided surgery systems market value from the PDE system segment is slated to witness robust growth rate over 2024-2032 due to its ability to enhance the detection and treatment of various diseases. PDE systems utilize fluorescent dyes that selectively accumulate in diseased tissues, making them highly visible under specialized imaging devices during surgery. This technology also allows surgeons to precisely identify tumor margins and residual cancerous cells that may not be visible to the naked eye or conventional imaging methods.
With respect to surgery, the fluorescence guided surgery systems industry from the laparascopic/endoscopic surgery segment is poised to depict significant CAGR from 2024 to 2032. The growth is favored by the increasing demand for minimally invasive procedures that offer reduced recovery times and fewer complications compared to traditional open surgeries. Fluorescence-guided systems also enhance the precision and safety of laparoscopic and endoscopic surgeries by providing real-time visualization of critical structures, such as blood vessels, lymph nodes, and tumors.
Asia Pacific fluorescence guided surgery systems industry is projected to depict sustained growth from 2024-2032. The increasing healthcare expenditure and infrastructure development across China, India, and Japan, are leading to heavy investments for upgrading medical facilities and adopting advanced surgical technologies. The rising incidence of cancer and other chronic diseases is also driving the need for innovative diagnostic and treatment solutions that enable more effective tumor detection. Rising advancements in healthcare technology and the growing awareness among healthcare providers about the benefits of fluorescence-guided surgery are also driving the regional market growth.